{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:54:48Z","timestamp":1790013288318,"version":"4.0.1"},"reference-count":320,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T00:00:00Z","timestamp":1640131200000},"content-version":"vor","delay-in-days":386,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jacc.2020.08.044","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T13:33:44Z","timestamp":1605879224000},"page":"3022-3055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":264,"title":["2020 AHA\/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary"],"prefix":"10.1016","volume":"76","author":[{"given":"Steve R.","family":"Ommen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Mital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharlene M.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Deswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren L.","family":"Evanovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Joglar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kantor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carey","family":"Kimmelstiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Kittleson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Maron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Y.","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartzell V.","family":"Schaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Semsarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sorajja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2020.08.044_bib1","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib2","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/j.jacc.2011.06.011","volume":"58","author":"Gersh","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib3","series-title":"Methodology Manual and Policies From the ACCF\/AHA Task Force on Practice Guidelines","year":"2010"},{"key":"10.1016\/j.jacc.2020.08.044_bib6","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/BF02595921","article-title":"Patients' participation in medical care: effects on blood sugar control and quality of life in diabetes","volume":"3","author":"Greenfield","year":"1988","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.jacc.2020.08.044_bib7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.7326\/0003-4819-102-4-520","article-title":"Expanding patient involvement in care. Effects on patient outcomes","volume":"102","author":"Greenfield","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2020.08.044_bib8","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1097\/00005650-198903001-00010","article-title":"Assessing the effects of physician-patient interactions on the outcomes of chronic disease","volume":"27","author":"Kaplan","year":"1989","journal-title":"Med Care"},{"key":"10.1016\/j.jacc.2020.08.044_bib9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0277-9536(98)00059-8","article-title":"Patient participation in decision-making","volume":"47","author":"Guadagnoli","year":"1998","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.jacc.2020.08.044_bib10","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamacardio.2016.0252","article-title":"Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003-2011","volume":"1","author":"Kim","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib11","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.amjcard.2014.07.075","article-title":"Results of ventricular septal myectomy and hypertrophic cardiomyopathy (from Nationwide Inpatient Sample [1998-2010])","volume":"114","author":"Panaich","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib12","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1161\/CIRCULATIONAHA.111.076257","article-title":"Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy","volume":"126","author":"Sorajja","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrcardio.2017.6","article-title":"Shared decision-making in HCM","volume":"14","author":"Maron","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib14","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1093\/eurheartj\/ehx370","article-title":"Standards defining a 'Heart Valve Centre': ESC Working Group on Valvular Heart Disease and European Association for Cardiothoracic Surgery Viewpoint","volume":"38","author":"Chambers","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib15","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2014.05.003","article-title":"Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine","volume":"64","author":"Maron","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib17","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2005.02.090","article-title":"Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy","volume":"46","author":"Ommen","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1161\/CIRCULATIONAHA.112.000849","article-title":"Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction","volume":"128","author":"Desai","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib19","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1540-8167.2008.01366.x","article-title":"Successful catheter ablation of hemodynamically unstable monomorphic ventricular tachycardia in a patient with hypertrophic cardiomyopathy and apical aneurysm","volume":"20","author":"Lim","year":"2009","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/CIRCEP.110.957290","article-title":"Long-term outcomes of combined epicardial and endocardial ablation of monomorphic ventricular tachycardia related to hypertrophic cardiomyopathy","volume":"4","author":"Dukkipati","year":"2011","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib21","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.amjcard.2017.12.044","article-title":"Impact of advanced therapies for improving survival to heart transplant in patients with hypertrophic cardiomyopathy","volume":"121","author":"Rowin","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib22","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1161\/CIRCHEARTFAILURE.114.001843","article-title":"Clinical spectrum, therapeutic options, and outcome of advanced heart failure in hypertrophic cardiomyopathy","volume":"8","author":"Pasqualucci","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2020.08.044_bib23","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jacc.2012.02.068","article-title":"Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives","volume":"60","author":"Maron","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib24","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.hrthm.2011.07.017","article-title":"The emerging role of the cardiac genetic counselor","volume":"8","author":"Ingles","year":"2011","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2020.08.044_bib25","doi-asserted-by":"crossref","DOI":"10.1161\/HCG.0000000000000054","article-title":"Establishment of specialized clinical cardiovascular genetics programs: recognizing the need and meeting standards: a scientific statement from the American Heart Association","volume":"12","author":"Ahmad","year":"2019","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.jacc.2020.08.044_bib26","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.117.001896","article-title":"Outcomes of contemporary family screening in hypertrophic cardiomyopathy","volume":"11","author":"van Velzen","year":"2018","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.jacc.2020.08.044_bib27","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1161\/CIRCULATIONAHA.114.013478","article-title":"Risk of cardiomyopathy in younger persons with a family history of death from cardiomyopathy: a nationwide family study in a cohort of 3.9 million persons","volume":"132","author":"Ranthe","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib28","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1093\/eurheartj\/ehz396","article-title":"Family screening for hypertrophic cardiomyopathy: is it time to change practice guidelines?","volume":"40","author":"Lafreniere-Roula","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib29","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.amjcard.2006.07.029","article-title":"Determinants for clinical diagnosis of hypertrophic cardiomyopathy","volume":"98","author":"Adabag","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib30","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jcmg.2008.09.002","article-title":"Echocardiography in hypertrophic cardiomyopathy: the role of conventional and emerging technologies","volume":"1","author":"Afonso","year":"2008","journal-title":"J Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2020.08.044_bib31","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/0735-1097(95)00390-8","article-title":"Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients","volume":"26","author":"Klues","year":"1995","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0033-0620(85)90024-6","article-title":"Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review","volume":"28","author":"Wigle","year":"1985","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2020.08.044_bib33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0735-1097(83)80269-1","article-title":"Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study","volume":"2","author":"Shapiro","year":"1983","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib34","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.echo.2011.03.006","article-title":"American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy","volume":"24","author":"Nagueh","year":"2011","journal-title":"J Am Soc Echocardiogr."},{"key":"10.1016\/j.jacc.2020.08.044_bib35","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jacc.2010.11.002","volume":"57","author":"Douglas","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib36","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1093\/eurheartj\/ehq136","article-title":"Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy","volume":"31","author":"Melacini","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib37","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/hrt.2003.031161","article-title":"Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy","volume":"91","author":"Thaman","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2020.08.044_bib38","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/CIRCULATIONAHA.105.583500","article-title":"Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy","volume":"114","author":"Harris","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib39","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/CIRCHEARTFAILURE.112.967026","article-title":"Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging","volume":"5","author":"Olivotto","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2020.08.044_bib40","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacc.2012.03.076","article-title":"Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy","volume":"60","author":"Todiere","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib41","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/europace\/euz118","article-title":"A\u00a0validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy","volume":"21","author":"Norrish","year":"2019","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2020.08.044_bib42","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.hrthm.2019.04.040","article-title":"Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: an international multicenter study","volume":"16","author":"Balaji","year":"2019","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2020.08.044_bib43","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJMoa021332","article-title":"Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy","volume":"348","author":"Maron","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.08.044_bib44","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1161\/01.CIR.0000162460.36735.71","article-title":"Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy","volume":"111","author":"Woo","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib45","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1161\/CIRCULATIONAHA.107.698985","article-title":"Evaluation of left ventricular filling pressures by doppler echocardiography in patients with hypertrophic cardiomyopathy","volume":"116","author":"Geske","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib46","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.107.742395","article-title":"Quantifying diastolic function in hypertrophic cardiomyopathy: the ongoing search for the holy grail","volume":"116","author":"Rakowski","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib47","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.echo.2018.01.022","article-title":"Standardized goal-directed Valsalva maneuver for assessment of inducible left ventricular outflow tract obstruction in hypertrophic cardiomyopathy","volume":"31","author":"Kumar","year":"2018","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2020.08.044_bib48","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0002-9149(99)80416-0","article-title":"Provocation of latent left ventricular outflow tract gradients with amyl nitrite and exercise in hypertrophic cardiomyopathy","volume":"75","author":"Marwick","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib49","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.echo.2010.10.006","article-title":"Standing and exercise Doppler echocardiography in obstructive hypertrophic cardiomyopathy: the range of gradients with upright activity","volume":"24","author":"Joshi","year":"2011","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2020.08.044_bib50","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib51","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.amjcard.2017.08.047","article-title":"Comparison of Valsalva maneuver, amyl nitrite, and exercise echocardiography to demonstrate latent left ventricular outflow obstruction in hypertrophic cardiomyopathy","volume":"120","author":"Ayoub","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib52","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/ejechocard\/jeq063","article-title":"Comparison of Valsalva manoeuvre and exercise in echocardiographic evaluation of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy","volume":"11","author":"Jensen","year":"2010","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.jacc.2020.08.044_bib53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ehjci\/jew313","article-title":"Upright treadmill vs. semi-supine bicycle exercise echocardiography to provoke obstruction in symptomatic hypertrophic cardiomyopathy: A pilot study","volume":"19","author":"Reant","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2020.08.044_bib54","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1136\/hrt.2007.126003","article-title":"Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy","volume":"94","author":"Shah","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2020.08.044_bib55","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0735-1097(92)90135-A","article-title":"Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making","volume":"20","author":"Grigg","year":"1992","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib56","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/0735-1097(92)90359-U","article-title":"Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy","volume":"20","author":"Marwick","year":"1992","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib57","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.echo.2017.11.016","article-title":"Intraoperative two- and three-dimensional transesophageal echocardiography in combined myectomy-mitral operations for hypertrophic cardiomyopathy","volume":"31","author":"Nampiaparampil","year":"2018","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2020.08.044_bib58","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S0002-9149(02)02694-2","article-title":"Impact of intraoperative transesophageal echocardiography in the surgical management of hypertrophic cardiomyopathy","volume":"90","author":"Ommen","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib59","first-page":"462","article-title":"Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: detection of threatening myocardial necrosis distant from the septal target area","volume":"47","author":"Faber","year":"1999","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2020.08.044_bib60","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1067\/mje.2000.108250","article-title":"Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring","volume":"13","author":"Faber","year":"2000","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2020.08.044_bib61","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jcmg.2015.04.006","article-title":"Role of imaging in the evaluation of patients at risk for sudden cardiac death: genotype-phenotype intersection","volume":"8","author":"Nagueh","year":"2015","journal-title":"J Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2020.08.044_bib62","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.euje.2004.01.001","article-title":"Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience","volume":"5","author":"Faber","year":"2004","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.jacc.2020.08.044_bib63","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1053\/euhj.1999.1692","volume":"20","author":"Kuhn","year":"1999","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib64","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.107.738740","article-title":"Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy","volume":"118","author":"Sorajja","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib65","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1161\/01.CIR.98.22.2415","article-title":"Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography","volume":"98","author":"Faber","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib66","first-page":"1994","article-title":"Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery","volume":"38","author":"Qin","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib67","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.111.090514","article-title":"Penetrance of hypertrophic cardiomyopathy in children and adolescents","volume":"127","author":"Jensen Morten","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib68","unstructured":"Deleted in press."},{"key":"10.1016\/j.jacc.2020.08.044_bib69","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/CIRCULATIONAHA.118.037264","article-title":"Clinical course and significance of hypertrophic cardiomyopathy without left ventricular hypertrophy","volume":"139","author":"Maurizi","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib70","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.118.038846","article-title":"Yield of clinical screening for hypertrophic cardiomyopathy in child first-degree relatives","volume":"140","author":"Norrish","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib71","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jpeds.2017.03.033","article-title":"Penetrance of hypertrophic cardiomyopathy in children who are mutation positive","volume":"188","author":"Vermeer","year":"2017","journal-title":"J Pediatr"},{"key":"10.1016\/j.jacc.2020.08.044_bib72","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0894-7317(00)90026-9","article-title":"Apical hypertrophic cardiomyopathy: echocardiographic diagnosis with the use of intravenous contrast image enhancement","volume":"13","author":"Thanigaraj","year":"2000","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2020.08.044_bib73","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.echo.2017.11.013","article-title":"Clinical applications of ultrasonic enhancing agents in echocardiography: 2018 American Society of Echocardiography guidelines update","volume":"31","author":"Porter","year":"2018","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2020.08.044_bib74","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jacc.2009.05.006","article-title":"Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance","volume":"54","author":"Maron","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib75","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1161\/CIRCULATIONAHA.104.507723","article-title":"Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy","volume":"112","author":"Rickers","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib76","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/hrt.2003.014969","article-title":"Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography","volume":"90","author":"Moon","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2020.08.044_bib77","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.006309","article-title":"Discrepant measurements of maximal left ventricular wall thickness between cardiac magnetic resonance imaging and echocardiography in patients with hypertrophic cardiomyopathy","volume":"10","author":"Hindieh","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2020.08.044_bib78","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10554-016-0858-4","article-title":"Left ventricular wall thickness in patients with hypertrophic cardiomyopathy: a comparison between cardiac magnetic resonance imaging and echocardiography","volume":"32","author":"Corona-Villalobos","year":"2016","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2020.08.044_bib79","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.amjcard.2016.11.010","article-title":"Comparison of maximal wall thickness in hypertrophic cardiomyopathy differs between magnetic resonance imaging and transthoracic echocardiography","volume":"119","author":"Bois","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib80","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005372","article-title":"How to image hypertrophic cardiomyopathy","volume":"10","author":"Maron","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2020.08.044_bib81","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jacc.2016.11.063","article-title":"Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management","volume":"69","author":"Rowin","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib82","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10554-013-0355-y","article-title":"Evaluation of apical pouches in hypertrophic cardiomyopathy using cardiac MRI","volume":"30","author":"Kebed","year":"2014","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2020.08.044_bib83","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.amjcard.2010.01.367","article-title":"Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance","volume":"105","author":"Maron","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib84","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jcmg.2016.02.031","article-title":"Prognostic value of LGE-CMR in HCM: a meta-analysis","volume":"9","author":"Weng","year":"2016","journal-title":"J Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2020.08.044_bib85","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","article-title":"Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy","volume":"130","author":"Chan","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib86","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jacc.2018.05.060","article-title":"Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function","volume":"72","author":"Mentias","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib87","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1136\/heartjnl-2013-305471","article-title":"Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy","volume":"100","author":"Ismail","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2020.08.044_bib88","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.115.003132","article-title":"Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy patients without severe septal hypertrophy: implications of mitral valve and papillary muscle abnormalities assessed using cardiac magnetic resonance and echocardiography","volume":"8","author":"Patel","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2020.08.044_bib89","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.amjcard.2018.06.055","article-title":"Clinical spectrum and management implications of left ventricular outflow obstruction with mild ventricular septal thickness in hypertrophic cardiomyopathy","volume":"122","author":"Rowin","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib90","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.jacc.2016.01.071","article-title":"The mitral valve in obstructive hypertrophic cardiomyopathy: a test in context","volume":"67","author":"Sherrid","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib91","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/hrt.2007.118018","article-title":"Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy","volume":"94","author":"Kwon","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2020.08.044_bib92","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.amjcard.2013.01.340","article-title":"Papillary muscle insertion directly into the anterior mitral leaflet in hypertrophic cardiomyopathy, its identification and cause of outflow obstruction by cardiac magnetic resonance imaging, and its surgical management","volume":"111","author":"Rowin","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib93","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10554-013-0358-8","article-title":"Hypertrophic cardiomyopathy in cardiac CT: a validation study on the detection of intramyocardial fibrosis in consecutive patients","volume":"30","author":"Langer","year":"2014","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2020.08.044_bib94","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.ejrad.2014.05.035","article-title":"Quantification of myocardial delayed enhancement and wall thickness in hypertrophic cardiomyopathy: multidetector computed tomography versus magnetic resonance imaging","volume":"83","author":"Zhao","year":"2014","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib95","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1542-474X.2001.tb00118.x","article-title":"The electrocardiogram as a diagnostic tool for hypertrophic cardiomyopathy: revisited","volume":"6","author":"Maron","year":"2001","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib96","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/0002-9149(89)90187-2","article-title":"Relation of electrocardiographic abnormalities to evolving left ventricular hypertrophy in hypertrophic cardiomyopathy during childhood","volume":"63","author":"Panza","year":"1989","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib97","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/bjsports-2016-097438","article-title":"Accuracy of the ECG for differential diagnosis between hypertrophic cardiomyopathy and athlete's heart: comparison between the European Society of Cardiology (2010) and International (2017) criteria","volume":"52","author":"Zorzi","year":"2018","journal-title":"Br J Sports Med"},{"key":"10.1016\/j.jacc.2020.08.044_bib98","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/0002-9149(81)90604-4","article-title":"Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study","volume":"48","author":"Maron","year":"1981","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib99","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0735-1097(03)00827-1","article-title":"Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients","volume":"42","author":"Monserrat","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib100","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2004.11.043","article-title":"Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy","volume":"45","author":"Adabag","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib101","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.jacc.2017.03.003","article-title":"2017 ACC\/AHA\/HRS guideline for the evaluation and management of patients with syncope: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"70","author":"Shen","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.jacc.2020.08.044_bib102","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/jce.12982","article-title":"High incidence of de novo and subclinical atrial fibrillation in patients with hypertrophic cardiomyopathy and cardiac rhythm management device","volume":"27","author":"Wilke","year":"2016","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib103","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.amjcard.2016.08.092","article-title":"Incidence of device-detected atrial fibrillation and long-term outcomes in patients with hypertrophic cardiomyopathy","volume":"119","author":"van Velzen","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib104","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.117.029267","article-title":"Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy","volume":"136","author":"Rowin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib105","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1016\/j.amjcard.2017.02.040","article-title":"Occurrence and natural history of clinically silent episodes of atrial fibrillation in hypertrophic cardiomyopathy","volume":"119","author":"Rowin","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib106","article-title":"Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population","volume":"3","author":"Siontis","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2020.08.044_bib107","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jcin.2011.02.014","article-title":"Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy","volume":"4","author":"Geske","year":"2011","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.jacc.2020.08.044_bib108","first-page":"962","article-title":"Hemodynamic changes in systolic and diastolic function during isoproterenol challenge predicts symptomatic response to myectomy in hypertrophic cardiomyopathy with labile obstruction","volume":"88","author":"Prasad","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2020.08.044_bib109","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.amjcard.2007.09.111","article-title":"Utility of isoproterenol to provoke outflow tract gradients in patients with hypertrophic cardiomyopathy","volume":"101","author":"Elesber","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib110","first-page":"e39","article-title":"Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease","volume":"70","author":"Sorajja","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.jacc.2020.08.044_bib111","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jtcvs.2013.06.046","article-title":"Assessment of coronary artery disease risk in 5463 patients undergoing cardiac surgery: When is preoperative coronary angiography necessary?","volume":"146","author":"Thalji","year":"2013","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2020.08.044_bib112","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0735-1097(02)01950-2","article-title":"Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy","volume":"40","author":"Ciampi","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib113","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCHEARTFAILURE.114.002248","article-title":"Cardiopulmonary exercise testing and prognosis in hypertrophic cardiomyopathy","volume":"8","author":"Coats","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2020.08.044_bib114","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1253\/circj.CJ-16-0432","article-title":"Heart failure progression in hypertrophic cardiomyopathy-possible insights from cardiopulmonary exercise testing","volume":"80","author":"Magri","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2020.08.044_bib115","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.amjcard.2012.12.026","article-title":"Antihypertensive therapy in hypertrophic cardiomyopathy","volume":"111","author":"Argulian","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib116","unstructured":"Deleted in press."},{"key":"10.1016\/j.jacc.2020.08.044_bib117","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1093\/eurheartj\/ehq271","article-title":"Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"31","author":"Charron","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib118","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/gim.2013.44","article-title":"Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy","volume":"15","author":"Ingles","year":"2013","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2020.08.044_bib119","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/gim.2014.205","article-title":"Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity","volume":"17","author":"Alfares","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2020.08.044_bib120","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jacc.2018.04.078","article-title":"Whole genome sequencing improves outcomes of genetic testing in patients with hypertrophic cardiomyopathy","volume":"72","author":"Bagnall","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib121","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRE)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib122","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.119.002460","article-title":"Evaluating the clinical validity of hypertrophic cardiomyopathy genes","volume":"12","author":"Ingles","year":"2019","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.jacc.2020.08.044_bib123","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGENETICS.117.001916","article-title":"Pathogenicity of hypertrophic cardiomyopathy variants: a path forward together","volume":"10","author":"Ingles","year":"2017","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacc.2020.08.044_bib124","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.2009.371","article-title":"Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy","volume":"301","author":"Maron","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2020.08.044_bib125","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCIMAGING.110.957936","article-title":"Imaging phenotype versus genotype in hypertrophic cardiomyopathy","volume":"4","author":"Desai","year":"2011","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2020.08.044_bib126","unstructured":"Deleted in press."},{"key":"10.1016\/j.jacc.2020.08.044_bib127","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2020.08.044_bib128","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/cge.13024","article-title":"Clinical genetic testing in pediatric cardiomyopathy: is bigger better?","volume":"93","author":"Ouellette","year":"2018","journal-title":"Clin Genet"},{"key":"10.1016\/j.jacc.2020.08.044_bib129","unstructured":"Deleted in press."},{"key":"10.1016\/j.jacc.2020.08.044_bib130","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa075463","article-title":"Shared genetic causes of cardiac hypertrophy in children and adults","volume":"358","author":"Morita","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.08.044_bib131","unstructured":"Deleted in press."},{"key":"10.1016\/j.jacc.2020.08.044_bib132","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/eurheartj\/ehr092","article-title":"Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy","volume":"32","author":"Christiaans","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib133","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/eurheartj\/ehv063","article-title":"Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives","volume":"36","author":"Semsarian","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib134","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa1510687","article-title":"A\u00a0prospective study of sudden cardiac death among children and young adults","volume":"374","author":"Bagnall","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.08.044_bib135","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/gim.2013.138","article-title":"Determining pathogenicity of genetic variants in hypertrophic cardiomyopathy: importance of periodic reassessment","volume":"16","author":"Das","year":"2014","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2020.08.044_bib136","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMsa1507092","article-title":"Genetic misdiagnoses and the potential for health disparities","volume":"375","author":"Manrai","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.08.044_bib137","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/cge.13157","article-title":"Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy","volume":"93","author":"Mathew","year":"2018","journal-title":"Clin Genet"},{"key":"10.1016\/j.jacc.2020.08.044_bib138","doi-asserted-by":"crossref","first-page":"e001620","DOI":"10.1161\/CIRCGENETICS.116.001620","article-title":"Nonfamilial hypertrophic cardiomyopathy: prevalence, natural history, and clinical implications","volume":"10","author":"Ingles","year":"2017","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacc.2020.08.044_bib139","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1136\/jmg.2005.033886","article-title":"Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling","volume":"42","author":"Ingles","year":"2005","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.jacc.2020.08.044_bib140","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/gim.2012.19","article-title":"Communicating new knowledge on previously reported genetic variants","volume":"14","author":"Aronson","year":"2012","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2020.08.044_bib141","unstructured":"Deleted in press."},{"key":"10.1016\/j.jacc.2020.08.044_bib142","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41436-018-0391-z","article-title":"Patient re-contact after revision of genomic test results: points to consider\u2014a statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"21","author":"David","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2020.08.044_bib143","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s41436-019-0478-1","article-title":"Points to consider in the reevaluation and reanalysis of genomictest results: a statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"21","author":"Deignan","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2020.08.044_bib144","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.111.090514","article-title":"Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testing","volume":"127","author":"Jensen","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib145","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ijcard.2011.07.095","article-title":"Natural history of genotype positive\u2013phenotype negative patients with hypertrophic cardiomyopathy","volume":"152","author":"Gray","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib146","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1001\/jamacardio.2019.1391","article-title":"Enhanced American College of Cardiology\/American Heart Association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy","volume":"4","author":"Maron","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib147","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1161\/CIRCULATIONAHA.117.030437","article-title":"International external validation study of the 2014 European Society of Cardiology guidelines on sudden cardiac death prevention in hypertrophic cardiomyopathy (EVIDENCE-HCM)","volume":"137","author":"O'Mahony","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib148","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0735-1097(99)00056-X","article-title":"Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy","volume":"33","author":"Elliott","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib149","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1161\/CIRCULATIONAHA.108.798314","article-title":"Syncope and risk of sudden death in hypertrophic cardiomyopathy","volume":"119","author":"Spirito","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib150","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.amjcard.2010.06.077","article-title":"Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy","volume":"106","author":"Bos","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib151","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1093\/eurheartj\/ehq308","article-title":"Sudden death in hypertrophic cardiomyopathy: old risk factors re-assessed in a new model of maximalized follow-up","volume":"31","author":"Dimitrow","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib152","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJM200006153422403","article-title":"Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy","volume":"342","author":"Spirito","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.08.044_bib153","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2004.12.067","article-title":"The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms","volume":"45","author":"Autore","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib154","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0140-6736(00)04005-8","article-title":"Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy","volume":"357","author":"Elliott","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2020.08.044_bib155","first-page":"265","article-title":"Clinical significance of left ventricular apical aneurysms in hypertrophic cardiomyopathy patients: the role of diagnostic electrocardiography","volume":"64","author":"Ichida","year":"2014","journal-title":"J\u00a0Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib156","doi-asserted-by":"crossref","first-page":"e004604","DOI":"10.1161\/CIRCEP.116.004604","article-title":"Prognostic implications of nonsustained ventricular tachycardia in high-risk patients with hypertrophic cardiomyopathy","volume":"10","author":"Wang","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib157","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/eurheartj\/eht439","article-title":"A\u00a0novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD)","volume":"35","author":"O'Mahony","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib158","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.echo.2011.03.002","article-title":"Apical hypertrophic cardiomyopathy: prevalence and correlates of apical outpouching","volume":"24","author":"Binder","year":"2011","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2020.08.044_bib159","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.jacc.2020.04.045","article-title":"Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction","volume":"75","author":"Rowin","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib160","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1161\/CIRCULATIONAHA.119.044366","article-title":"Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe registry","volume":"141","author":"Marstrand","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib161","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/heartjnl-2012-303271","volume":"99","author":"O'Mahony","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2020.08.044_bib162","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.298.4.405","article-title":"Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy","volume":"298","author":"Maron","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2020.08.044_bib163","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ahj.2013.06.009","article-title":"Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications","volume":"166","author":"Vriesendorp","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib164","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2013.01.037","article-title":"Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy","volume":"61","author":"Maron","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib165","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1177\/2047487317702519","article-title":"Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"24","author":"Norrish","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib166","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1007\/s00246-011-9967-y","article-title":"Long-term follow-up of children and adolescents diagnosed with hypertrophic cardiomyopathy: risk factors for adverse arrhythmic events","volume":"32","author":"Moak","year":"2011","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib167","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0735-1097(98)00493-8","article-title":"Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy","volume":"32","author":"Yetman","year":"1998","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib168","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/j.jacc.2015.03.552","article-title":"Sudden death in childhood cardiomyopathy: results from a long-term national population-based study","volume":"65","author":"Bharucha","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib169","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00246-013-0676-6","article-title":"Implanted defibrillators in young hypertrophic cardiomyopathy patients: a multicenter study","volume":"34","author":"Kamp","year":"2013","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib170","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/CIRCULATIONAHA.115.017633","article-title":"Hypertrophic cardiomyopathy in children, adolescents, and young adults associated with low cardiovascular mortality with contemporary management strategies","volume":"133","author":"Maron","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib171","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1161\/CIRCULATIONAHA.120.047235","article-title":"A\u00a0validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy","volume":"142","author":"Miron","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib172","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.amjcard.2013.12.034","article-title":"Clinical significance of late gadolinium enhancement in patients <20 years of age with hypertrophic cardiomyopathy","volume":"113","author":"Smith","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib173","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/CIRCULATIONAHA.117.032966","article-title":"Prevalence and progression of late gadolinium enhancement in children and adolescents with hypertrophic cardiomyopathy","volume":"138","author":"Axelsson Raja","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib174","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1161\/CIRCULATIONAHA.117.027828","article-title":"Safety of sports for athletes with implantable cardioverter-defibrillators: long-term results of a prospective multinational registry","volume":"135","author":"Lampert","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib175","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002418","article-title":"Transvenous implantable cardioverter-defibrillator (ICD) lead performance: a meta-analysis of observational studies","volume":"4","author":"Providencia","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2020.08.044_bib176","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1161\/CIRCULATIONAHA.110.975219","article-title":"Longevity of Sprint Fidelis implantable cardioverter-defibrillator leads and risk factors for failure: implications for patient management","volume":"123","author":"Hauser","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib177","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.hrthm.2008.08.021","article-title":"Safety and efficacy of transvenous high-voltage implantable cardioverter-defibrillator leads in high-risk hypertrophic cardiomyopathy patients","volume":"5","author":"Hauser","year":"2008","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2020.08.044_bib178","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/hrt.2010.217182","article-title":"The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy","volume":"98","author":"O'Mahony","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2020.08.044_bib179","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/eurheartj\/ehu112","article-title":"Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry","volume":"35","author":"Lambiase","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib180","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.hrthm.2016.01.001","article-title":"Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts","volume":"13","author":"Lambiase","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2020.08.044_bib181","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00392-015-0901-9","article-title":"Long-term follow-up of subcutaneous ICD systems in patients with hypertrophic cardiomyopathy: a single-center experience","volume":"105","author":"Frommeyer","year":"2016","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib182","doi-asserted-by":"crossref","first-page":"e002488","DOI":"10.1161\/JAHA.115.002488","article-title":"Subcutaneous implantable cardioverter defibrillator in patients with hypertrophic cardiomyopathy: an initial experience","volume":"5","author":"Weinstock","year":"2016","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.jacc.2020.08.044_bib183","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.117.004801","article-title":"Disease severity and exercise testing reduce subcutaneous implantable cardioverter-defibrillator left sternal ECG screening success in hypertrophic cardiomyopathy","volume":"10","author":"Srinivasan","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib184","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.hrthm.2017.06.022","article-title":"Role of exercise electrocardiogram to screen for T-wave oversensing after implantation of subcutaneous implantable cardioverter-defibrillator","volume":"14","author":"Afzal","year":"2017","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2020.08.044_bib185","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.hrthm.2017.11.020","article-title":"Implantable cardioverter-defibrillator therapy in hypertrophic cardiomyopathy: a SIMPLE substudy","volume":"15","author":"Vamos","year":"2018","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2020.08.044_bib186","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/jce.13121","article-title":"Prognostic implications of defibrillation threshold testing in patients with hypertrophic cardiomyopathy","volume":"28","author":"Francia","year":"2017","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib187","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1253\/circj.CJ-16-0428","article-title":"Single-coil defibrillator leads yield satisfactory defibrillation safety margin in hypertrophic cardiomyopathy","volume":"80","author":"Okamura","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2020.08.044_bib188","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1540-8167.2010.01943.x","article-title":"Defibrillation thresholds in hypertrophic cardiomyopathy","volume":"22","author":"Quin","year":"2011","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib189","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1161\/CIRCULATIONAHA.105.594531","article-title":"Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the Detect Supraventricular Tachycardia Study","volume":"113","author":"Friedman","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib190","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1016\/j.jacc.2004.09.039","article-title":"Prevention of inappropriate therapy in implantable cardioverter-defibrillators: results of a prospective, randomized study of tachyarrhythmia detection algorithms","volume":"44","author":"Theuns","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib191","first-page":"611","article-title":"Reduced risk for inappropriate implantable cardioverter-defibrillator shocks with dual-chamber therapy compared with single-chamber therapy: results of the randomized OPTION study","volume":"2","author":"Kolb","year":"2014","journal-title":"J Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2020.08.044_bib192","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006937","volume":"6","author":"Peterson","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2020.08.044_bib193","first-page":"1478","article-title":"Dual- vs. single-chamber defibrillators for primary prevention of sudden cardiac death: long-term follow-up of the defibrillateur automatique implantable-prevention primaire registry","volume":"19","author":"Defaye","year":"2017","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.jacc.2020.08.044_bib194","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.hlc.2015.07.008","article-title":"Efficiencies and complications of dual chamber versus single chamber implantable cardioverter defibrillators in secondary sudden cardiac death prevention: a meta-analysis","volume":"25","author":"Hu","year":"2016","journal-title":"Lung Cir"},{"key":"10.1016\/j.jacc.2020.08.044_bib195","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0735-1097(96)00473-1","article-title":"Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial","volume":"29","author":"Nishimura","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib196","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/oxfordjournals.eurheartj.a015435","article-title":"Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group","volume":"18","author":"Kappenberger","year":"1997","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib197","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1161\/01.CIR.99.22.2927","article-title":"Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY)","volume":"99","author":"Maron","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib198","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1023\/B:JICE.0000035929.84238.2f","article-title":"Doppler evaluation of the descending aorta in patients with hypertrophic cardiomyopathy: potential for assessing the functional significance of outflow tract gradients and for optimizing pacemaker function","volume":"11","author":"Mickelsen","year":"2004","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib199","first-page":"82","article-title":"Cardiac resynchronization therapy in patients with end-stage hypertrophic cardiomyopathy","volume":"20","author":"Killu","year":"2018","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.jacc.2020.08.044_bib200","first-page":"238","article-title":"Clinical outcome of cardiac resynchronization therapy in dilated-phase hypertrophic cardiomyopathy","volume":"14","author":"Gu","year":"2017","journal-title":"J\u00a0Geriatr Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib201","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ejheart.2008.03.006","article-title":"Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end-stage hypertrophic cardiomyopathy","volume":"10","author":"Rogers","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2020.08.044_bib202","first-page":"131","article-title":"Benefit of cardiac resynchronization therapy in end-stage nonobstructive hypertrophic cardiomyopathy","volume":"5","author":"Rowin","year":"2019","journal-title":"J Am Coll Cardiol EP"},{"key":"10.1016\/j.jacc.2020.08.044_bib203","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jacc.2017.11.040","article-title":"Cardiac resynchronization therapy for end-stage hypertrophic cardiomyopathy: the need for disease-specific criteria","volume":"71","author":"Cappelli","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib204","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/01.CIR.35.5.847","article-title":"Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade","volume":"35","author":"Cohen","year":"1967","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib205","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/hrt.32.6.804","article-title":"Long-term propranolol therapy in muscular subaortic stenosis","volume":"32","author":"Adelman","year":"1970","journal-title":"Br Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib206","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/0002-9149(73)90012-X","article-title":"Hypertrophic subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy","volume":"31","author":"Stenson","year":"1973","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib207","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/01.CIR.64.4.787","article-title":"Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy","volume":"64","author":"Bonow","year":"1981","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib208","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1161\/01.CIR.60.6.1208","article-title":"Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status","volume":"60","author":"Rosing","year":"1979","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib209","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1536\/ihj.27.701","article-title":"Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study","volume":"27","author":"Toshima","year":"1986","journal-title":"Jpn Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib210","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib211","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122","article-title":"Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with beta-blockade or verapamil","volume":"6","author":"Sherrid","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2020.08.044_bib212","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005152","article-title":"Safety of outpatient initiation of disopyramide for obstructive hypertrophic cardiomyopathy patients","volume":"6","author":"Adler","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2020.08.044_bib213","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jacc.2015.06.1333","article-title":"Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction","volume":"66","author":"Maron","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib214","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0002-9149(62)90373-9","article-title":"Hemogynamic alterations in idiopathic hypertrophic subaortic stenosis induced by sympathomimetic drugs","volume":"10","author":"Braunwald","year":"1962","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib215","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/adc.62.12.1265","article-title":"Cardiovascular collapse after verapamil in supraventricular tachycardia","volume":"62","author":"Kirk","year":"1987","journal-title":"Arc Dis Child"},{"key":"10.1016\/j.jacc.2020.08.044_bib216","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/HCO.0000000000000200","article-title":"Mitral valve and papillary muscle abnormalities in hypertrophic obstructive cardiomyopathy","volume":"30","author":"Teo","year":"2015","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib217","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jtcvs.2011.10.096","article-title":"Asymmetric septal hypertrophy in patients with severe aortic stenosis: the usefulness of associated septal myectomy","volume":"145","author":"Di Tommaso","year":"2013","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2020.08.044_bib218","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.athoracsur.2009.10.065","article-title":"Concomitant septal myectomy at the time of aortic valve replacement for severe aortic stenosis","volume":"89","author":"Kayalar","year":"2010","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacc.2020.08.044_bib219","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1016\/j.jacc.2018.09.064","article-title":"Survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy","volume":"72","author":"Batzner","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib220","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jtcvs.2018.08.062","article-title":"Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a propensity score-matched cohort","volume":"157","author":"Nguyen","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2020.08.044_bib221","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.118.007673","article-title":"Guideline-based referral for septal reduction therapy in obstructive hypertrophic cardiomyopathy is associated with excellent clinical outcomes","volume":"12","author":"Kimmelstiel","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2020.08.044_bib222","doi-asserted-by":"crossref","first-page":"100398","DOI":"10.1016\/j.cpcardiol.2018.10.002","article-title":"Significance of pulmonary hypertension in hypertrophic cardiomyopathy","volume":"45","author":"Mitra","year":"2020","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib223","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/ehjci\/jew024","article-title":"Pulmonary hypertension is associated with worse survival in hypertrophic cardiomyopathy","volume":"17","author":"Ong","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2020.08.044_bib224","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jcmg.2013.08.010","article-title":"Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes","volume":"7","author":"Desai","year":"2014","journal-title":"J Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2020.08.044_bib225","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.athoracsur.2018.03.039","article-title":"Determinants of reverse remodeling of the left atrium after transaortic myectomy","volume":"106","author":"Nguyen","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacc.2020.08.044_bib226","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/echo.13158","article-title":"Impact of septal reduction on left atrial size and diastole in hypertrophic cardiomyopathy","volume":"33","author":"Finocchiaro","year":"2016","journal-title":"Echocardiography"},{"key":"10.1016\/j.jacc.2020.08.044_bib227","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.amjcard.2015.11.016","article-title":"Usefulness of von Willebrand factor activity indexes to predict therapeutic response in hypertrophic cardiomyopathy","volume":"117","author":"Blackshear","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib228","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/jth.12780","article-title":"Remission of recurrent gastrointestinal bleeding after septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy-associated acquired von Willebrand syndrome","volume":"13","author":"Blackshear","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2020.08.044_bib229","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jtcvs.2018.03.150","article-title":"Prediction of sudden death risk in obstructive hypertrophic cardiomyopathy: potential for refinement of current criteria","volume":"156","author":"Desai","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2020.08.044_bib230","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1093\/eurheartj\/ehm117","article-title":"Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy","volume":"28","author":"McLeod","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib231","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jacc.2017.03.011","article-title":"2017 AHA\/ACC focused update of the 2014 AHA\/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"70","author":"Nishimura","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib232","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jacc.2009.01.079","article-title":"Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study","volume":"54","author":"Sorajja","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib233","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.jacc.2011.08.040","article-title":"Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment","volume":"58","author":"Ball","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib234","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.jtcvs.2018.11.148","article-title":"Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center","volume":"157","author":"Hodges","year":"2019","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2020.08.044_bib235","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2019.05.053","article-title":"Conduction abnormalities and long-term mortality following septal myectomy in patients with obstructive hypertrophic cardiomyopathy","volume":"74","author":"Cui","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib236","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.mayocp.2018.07.022","article-title":"Septal myectomy in hypertrophic cardiomyopathy: national outcomes of concomitant mitral surgery","volume":"94","author":"Holst","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2020.08.044_bib237","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.jacc.2016.07.735","article-title":"Mitral regurgitation in patients with hypertrophic obstructive cardiomyopathy: implications for concomitant valve procedures","volume":"68","author":"Hong","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib238","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/0002-8703(85)90357-6","article-title":"Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: an echographic study","volume":"109","author":"Bourmayan","year":"1985","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib239","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/hrt.48.3.204","article-title":"Non-invasive assessment of diastolic function in hypertrophic cardiomyopathy on and off beta adrenergic blocking drugs","volume":"48","author":"Alvares","year":"1982","journal-title":"Br Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib240","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/hrt.56.6.544","article-title":"Effects of verapamil on haemodynamic function and myocardial metabolism in patients with hypertrophic cardiomyopathy","volume":"56","author":"Wilmshurst","year":"1986","journal-title":"Br Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib241","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1161\/01.CIR.79.5.1052","article-title":"Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy","volume":"79","author":"Udelson","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib242","first-page":"146","article-title":"Hypertrophic cardiomyopathy in pediatric patients: effect of verapamil on regional and global left ventricular diastolic function","volume":"16","author":"Pacileo","year":"2000","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib243","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF03164924","article-title":"Effects of diltiazem on myocardial perfusion abnormalities during exercise in patients with hypertrophic cardiomyopathy","volume":"12","author":"Sugihara","year":"1998","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.jacc.2020.08.044_bib244","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/0735-1097(93)90386-F","article-title":"A\u00a0double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy","volume":"21","author":"Gilligan","year":"1993","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib245","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/eurheartj\/ehs150","article-title":"Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence","volume":"33","author":"Spoladore","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib246","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/01.CIR.67.2.413","article-title":"Hemodynamic effects of verapamil in children and adolescents with hypertrophic cardiomyopathy","volume":"67","author":"Spicer","year":"1983","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib247","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-8587(14)70241-4","article-title":"Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial","volume":"3","author":"Axelsson","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2020.08.044_bib248","article-title":"Apical myectomy for patients with hypertrophic cardiomyopathy and advanced heart failure","author":"Nguyen","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2020.08.044_bib249","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/heartjnl-2013-304276","article-title":"Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review","volume":"100","author":"Guttmann","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2020.08.044_bib250","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0735-1097(01)01727-2","article-title":"Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy","volume":"39","author":"Maron","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib251","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.chest.2018.11.009","article-title":"Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation with hypertrophic cardiomyopathy: a nationwide cohort study","volume":"155","author":"Jung","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2020.08.044_bib252","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1016\/j.jacc.2016.04.026","article-title":"Stroke and bleeding risks in NOAC- and warfarin-treated patients with hypertrophic cardiomyopathy and atrial fibrillation","volume":"67","author":"Noseworthy","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib253","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ijcard.2017.08.010","article-title":"Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation","volume":"248","author":"Dominguez","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib254","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/eurheartj\/ehx731","article-title":"Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis","volume":"39","author":"Mahajan","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib255","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/hc4601.097997","article-title":"Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy","volume":"104","author":"Olivotto","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib256","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/eurheartj\/eht491","article-title":"Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices)","volume":"35","author":"Boriani","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib257","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/europace\/euv339","article-title":"Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"18","author":"Zhao","year":"2016","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2020.08.044_bib258","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.hrthm.2015.03.042","article-title":"Outcomes of nonpharmacologic treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy","volume":"12","author":"Bassiouny","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2020.08.044_bib259","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.jacc.2015.08.856","article-title":"2015 ACC\/AHA\/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"67","author":"Page","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib260","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/eurheartj\/ehx042","article-title":"Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT","volume":"38","author":"Van Gelder","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib261","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/europace\/eux163","article-title":"Device-detected subclinical atrial tachyarrhythmias: definition, implications and management-an European Heart Rhythm Association (EHRA) consensus document","volume":"19","author":"Gorenek","year":"2017","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2020.08.044_bib262","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1161\/CIRCULATIONAHA.115.020252","article-title":"Clinical implications of brief device-detected atrial tachyarrhythmias in a cardiac rhythm management device population: results from the registry of atrial tachycardia and atrial fibrillation episodes","volume":"134","author":"Swiryn","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib263","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1105575","article-title":"Subclinical atrial fibrillation and the risk of stroke","volume":"366","author":"Healey","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.08.044_bib264","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1540-8167.2008.01320.x","article-title":"Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events","volume":"20","author":"Botto","year":"2009","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib265","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0735-1097(10)80014-2","article-title":"Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study","volume":"15","author":"Robinson","year":"1990","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib266","article-title":"Safety of outpatient initiation of disopyramide for obstructive hypertrophic cardiomyopathy patients","volume":"6","author":"Adler","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2020.08.044_bib267","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/pace.13310","article-title":"Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: a case series and literature review","volume":"41","author":"Moore","year":"2018","journal-title":"Pacing Clin Electrphysiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib268","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.amjcard.2019.02.051","article-title":"Safety, side effects and relative efficacy of medications for rhythm control of atrial fibrillation in hypertrophic cardiomyopathy","volume":"123","author":"Miller","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib269","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/heartjnl-2016-309406","article-title":"Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"102","author":"Providencia","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2020.08.044_bib270","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1161\/CIRCEP.113.000339","article-title":"Catheter ablation of atrial fibrillation in hypertrophic cardiomyopathy: long-term outcomes and mechanisms of arrhythmia recurrence","volume":"6","author":"Santangeli","year":"2013","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib271","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amjcard.2003.10.025","article-title":"Effectiveness of atrial fibrillation surgery in patients with hypertrophic cardiomyopathy","volume":"93","author":"Chen","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib272","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.jtcvs.2017.08.063","article-title":"Concomitant ablation for atrial fibrillation during septal myectomy in patients with hypertrophic obstructive cardiomyopathy","volume":"155","author":"Bogachev-Prokophiev","year":"2018","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2020.08.044_bib273","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/ejcts\/ezx017","article-title":"Mid-term outcomes of concomitant surgical ablation of atrial fibrillation in patients undergoing cardiac surgery for hypertrophic cardiomyopathydagger","volume":"51","author":"Lapenna","year":"2017","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jacc.2020.08.044_bib274","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1161\/CIRCHEARTFAILURE.114.001435","article-title":"Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy: under-recognized subset of candidates for heart transplant","volume":"7","author":"Rowin","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2020.08.044_bib275","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.295.2.165","article-title":"Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial","volume":"295","author":"Connolly","year":"2006","journal-title":"JAMA."},{"key":"10.1016\/j.jacc.2020.08.044_bib276","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.hrthm.2016.03.004","article-title":"Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Santangeli","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2020.08.044_bib277","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1540-8167.2011.02183.x","article-title":"Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies","volume":"23","author":"Baquero","year":"2012","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib278","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/FJC.0b013e31829651fe","article-title":"Mexiletine as an adjunctive therapy to amiodarone reduces the frequency of ventricular tachyarrhythmia events in patients with an implantable defibrillator","volume":"62","author":"Gao","year":"2013","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacc.2020.08.044_bib279","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jce.13194","article-title":"Ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy and defibrillators: triggers, treatment, and implications","volume":"28","author":"Link","year":"2017","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib280","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/europace\/euw260","article-title":"2015 HRS\/EHRA\/APHRS\/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing","volume":"19","author":"Wilkoff","year":"2017","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2020.08.044_bib281","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.hrthm.2010.05.022","article-title":"Radiofrequency catheter ablation of ventricular arrhythmias in patients with hypertrophic cardiomyopathy: safety and feasibility","volume":"7","author":"Santangeli","year":"2010","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2020.08.044_bib282","first-page":"339","article-title":"Radiofrequency catheter ablation of ventricular tachycardia in patients with hypertrophic cardiomyopathy and apical aneurysm","volume":"4","author":"Igarashi","year":"2018","journal-title":"J Am Coll Cardiol EP"},{"key":"10.1016\/j.jacc.2020.08.044_bib283","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib284","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.mayocp.2016.01.002","article-title":"The natural history of nonobstructive hypertrophic cardiomyopathy","volume":"91","author":"Hebl","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2020.08.044_bib285","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1016\/j.amjcard.2017.08.048","article-title":"Interaction of adverse disease related pathways in hypertrophic cardiomyopathy","volume":"120","author":"Rowin","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib286","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.amjcard.2012.04.030","article-title":"Cardiac transplantation in patients with hypertrophic cardiomyopathy","volume":"110","author":"Kato","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib287","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.transproceed.2013.12.052","article-title":"Long-term outcomes of orthotopic heart transplantation for hypertrophic cardiomyopathy","volume":"46","author":"Lee","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jacc.2020.08.044_bib288","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.healun.2015.03.012","article-title":"Role of ventricular assist therapy for patients with heart failure and restrictive physiology: improving outcomes for a lethal disease","volume":"34","author":"Grupper","year":"2015","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.jacc.2020.08.044_bib289","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/MAT.0b013e318286018d","article-title":"Centrifugal continuous-flow left ventricular assist device in patients with hypertrophic cardiomyopathy: a case series","volume":"59","author":"Muthiah","year":"2013","journal-title":"ASAIO J"},{"key":"10.1016\/j.jacc.2020.08.044_bib290","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.cardfail.2017.09.011","article-title":"Outcomes of restrictive and hypertrophic cardiomyopathies after LVAD: an INTERMACS analysis","volume":"23","author":"Patel","year":"2017","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacc.2020.08.044_bib291","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/CIRCHEARTFAILURE.110.959288","article-title":"Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy","volume":"4","author":"Topilsky","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2020.08.044_bib292","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.2017.2503","article-title":"Effect of moderate-intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy: a randomized clinical trial","volume":"317","author":"Saberi","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2020.08.044_bib293","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.amjcard.2018.05.023","article-title":"A\u00a0control theory-based pilot intervention to increase physical activity in patients with hypertrophic cardiomyopathy","volume":"122","author":"Sweeting","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib294","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib295","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1161\/CIRCULATIONAHA.117.029639","article-title":"Competitive sport participation among athletes with heart disease: a call for a paradigm shift in decision making","volume":"136","author":"Baggish","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib296","unstructured":"Deleted in press."},{"key":"10.1016\/j.jacc.2020.08.044_bib297","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/eurheartj\/ehy730","article-title":"Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC)","volume":"40","author":"Pelliccia","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib298","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1161\/CIRCULATIONAHA.112.000447","article-title":"Safety of sports for athletes with implantable cardioverter-defibrillators: results of a prospective, multinational registry","volume":"127","author":"Lampert","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib299","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2017.07.015","article-title":"Vigorous exercise in patients with hypertrophic cardiomyopathy","volume":"250","author":"Dejgaard","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib300","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1161\/CIRCULATIONAHA.117.031725","article-title":"Does sport participation worsen the clinical course of hypertrophic cardiomyopathy? Clinical outcome of hypertrophic cardiomyopathy in athletes","volume":"137","author":"Pelliccia","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib301","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1161\/CIRCULATIONAHA.117.031306","article-title":"Return-to-play for athletes with genetic heart diseases","volume":"137","author":"Turkowski","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.08.044_bib302","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib304","doi-asserted-by":"crossref","first-page":"s50","DOI":"10.1136\/heartjnl-2018-313058","article-title":"Heart muscle disease management in aircrew","volume":"105","author":"D'Arcy","year":"2019","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2020.08.044_bib305","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/ejhf.316","article-title":"Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA)","volume":"17","author":"Guttmann","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2020.08.044_bib306","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1093\/eurheartj\/ehy340","article-title":"2018 ESC guidelines for the management of cardiovascular diseases during pregnancy","volume":"39","author":"Regitz-Zagrosek","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib307","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12471-012-0358-7","article-title":"Pregnancy in women with hypertrophic cardiomyopathy","volume":"21","author":"Pieper","year":"2013","journal-title":"Neth Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib308","doi-asserted-by":"crossref","first-page":"77.e1","DOI":"10.1016\/j.ajog.2019.07.019","article-title":"Planned vaginal delivery and cardiovascular morbidity in pregnant women with heart disease","volume":"222","author":"Easter","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jacc.2020.08.044_bib309","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1093\/eurheartj\/ehx189","article-title":"Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC)","volume":"38","author":"Goland","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib310","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1136\/heart.89.7.752","article-title":"Pregnancy related complications in women with hypertrophic cardiomyopathy","volume":"89","author":"Thaman","year":"2003","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2020.08.044_bib311","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.acvd.2017.05.010","article-title":"Pregnancy in women with a cardiomyopathy: outcomes and predictors from a retrospective cohort","volume":"111","author":"Billebeau","year":"2018","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2020.08.044_bib312","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/S0735-1097(02)02495-6","article-title":"Risk associated with pregnancy in hypertrophic cardiomyopathy","volume":"40","author":"Autore","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib313","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib314","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.amjcard.2013.05.070","article-title":"Comparison of clinical presentation, left ventricular morphology, hemodynamics, and exercise tolerance in obese versus nonobese patients with hypertrophic cardiomyopathy","volume":"112","author":"Canepa","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib315","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jacc.2013.03.062","article-title":"Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy","volume":"62","author":"Olivotto","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib316","first-page":"1","article-title":"Association of obesity with adverse long-term outcomes in hypertrophic cardiomyopathy","author":"Fumagalli","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib317","first-page":"E447","article-title":"Predictors 1 of exercise capacity in patients with hypertrophic obstructive cardiomyopathy","volume":"7","author":"Smith","year":"2018","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jacc.2020.08.044_bib318","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/CIRCGENETICS.112.963363","article-title":"Toronto hypertrophic cardiomyopathy genotype score for prediction of a positive genotype in hypertrophic cardiomyopathy","volume":"6","author":"Gruner","year":"2013","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacc.2020.08.044_bib319","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/eurheartj\/ehv522","article-title":"Hypertrophic remodelling in cardiac regulatory myosin light chain (MYL2) founder mutation carriers","volume":"37","author":"Claes","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.08.044_bib320","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.jacc.2009.07.030","article-title":"High prevalence of abnormal nocturnal oximetry in patients with hypertrophic cardiomyopathy","volume":"54","author":"Eleid","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib321","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.amjcard.2010.01.023","article-title":"Interactions between sleep disordered breathing and atrial fibrillation in patients with hypertrophic cardiomyopathy","volume":"105","author":"Konecny","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.08.044_bib322","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1378\/chest.14-1498","article-title":"Decreased exercise capacity and sleep-disordered breathing in patients with hypertrophic cardiomyopathy","volume":"147","author":"Konecny","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2020.08.044_bib323","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.hrthm.2018.12.017","article-title":"Obstructive sleep apnea is associated with nonsustained ventricular tachycardia in patients with hypertrophic obstructive cardiomyopathy","volume":"16","author":"Wang","year":"2019","journal-title":"Heart Rhythm"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109720364123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109720364123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:39:59Z","timestamp":1760017199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109720364123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":320,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0735109720364123"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2020.08.044","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2020 AHA\/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2020.08.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Heart Association, Inc., and the American College of Cardiology. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}